Characterisation of Haemolytic Uropathogenic Escherichia coli Isolated From Dogs and Cats Authors: Sarah Büttner, Joachim Spergser, Olga Makarova, Michael P. Szostak, Adriana Cabal Rosel, Werner Ruppitsch, Sabine Schäfer‐Somi, Elke Müller, Sascha D. Braun, Stefan Monecke, Ralf Ehricht, Frank Künzel, Igor Loncaric Published: 2026 ABSTRACT ABSTRACTBackground Escherichia (E.) coli is the primary cause of urinary tract infections in companion animals.ObjectivesTherefore, the present study aimed to characterise antimicrobial resistance profiles, virulence‐associated genes, and phylogenetic diversity of E. coli with haemolytic colony morphology isolated from urine samples of cats and dogs during routine diagnostic activities, which have not been characterised previously in Austria.MethodsA total of 51 isolates were included from dogs (n = 32) and cats (n = 19) and characterised by a polyphasic approach, including susceptibility testing and DNA microarray‐based assays. In addition, all isolates were analysed using two‐locus fumC and fimH sequence typing (CH‐clonotyping) and E. coli phylotyping.ResultsThe majority of E. coli isolates belonged to phylogenetic group B2, with one isolate assigned to phylogenetic group B1. Thirty‐four CH‐clonotypes were detected using two‐locus sequence typing. All isolates detected could be classified as ExPEC.ConclusionsThe identification of clonal complexes common to humans indicates interspecies transmission, thereby emphasising the critical need for surveillance in companion animal populations. Introduction Escherichia (E.) coli plays a significant role in acute infections in humans and pets, both gastrointestinal and extraintestinal (Tchesnokova et al. 2016). The pathotype of extraintestinal pathogenic E. coli (ExPEC) can be divided into different subpathotypes, such as uropathogenic E. coli (UPEC), avian pathogenic E. coli (APEC), and sepsis‐associated E. coli (SPEC), among others, based on phylogenetic group affiliations and a combination of virulence factors (Hutton et al. 2018). Infections caused by ExPEC include urinary tract infections (UTIs), sepsis, pneumonia, meningitis, skin and soft tissue infections, and osteomyelitis (Hutton et al. 2018). With infections of the urogenital tract being the reportedly most frequently diagnosed infectious disease in dogs, UPEC causes the majority of UTIs in both humans and animals (Kidsley et al. 2020; Aurich et al. 2023). The pathogenicity of UPEC arises from virulence mechanisms that enable it to colonise and proliferate in the epithelial cells of the bladder (Kidsley et al. 2020). This includes fimbrial adhesins, most commonly Type 1 fimbriae, which are extracellular protein structures that allow UPEC to attach to bladder cells (Whelan et al. 2023; Lüthje and Brauner 2014). Ristow and Welch (2016) describe alpha‐haemolysin as a commonly observed virulence factor in severe cases of UTIs in humans, with a correlation between the expression of haemolysin and the severity of infection. Alpha‐haemolysin (HlyA) (encoded by the hlyCABD operon) causes the lysis of red blood cells and exhibits cytotoxic activity against a variety of species and cell types. Extensive biochemical, electrophysiological, and structural studies using whole cells, erythrocytes, artificial membranes, and lipid bilayers have thoroughly demonstrated the pore‐forming action of HlyA in E. coli. Experimental data consistently show that HlyA inserts into target cell membranes, creating defined transmembrane pores. This action results in the lysis of the target cell due to the loss of its membrane integrity. Crucially, the detailed mechanism, including the dimensions, conductance properties, and precise process of pore formation, has been fully characterised through these experiments (Ristow and Welch 2016). Ristow and Welch indicate that approximately 50% of UPEC encode HlyA. Still, with increasing severity of infection, the proportion of the population expressing HlyA increases, with up to 78% of cases of pyelonephritis caused by UPEC encoding HlyA (Ristow and Welch 2016). In addition, hlyA genes in E. coli isolates were also associated with UTIs from companion animals (Ksiezarek et al. 2021; Siqueira et al. 2009; Siqueira et al. 2021; Melo et al. 2022; Jousserand et al. 2025; Valat et al. 2020). Therefore, the aim of the present study was to analyse E. coli with haemolytic activity on sheep blood agar isolated from urine samples of dogs and cats with signs of UTIs. Materials and Methods A total of 51 haemolytic E. coli isolates were collected between 2017 and 2023 during diagnostic activities at the Institute for Microbiology of the Veterinary University in Vienna. All these clinical samples were received from third parties and, therefore, are not subject to the reporting obligations of the Ethics and Animal Welfare Commission of the University of Veterinary Medicine in Vienna. Isolates were stored at −80°C in cryoprotectant medium for further characterisation. Isolates were obtained from urine samples of dogs (n = 32) and cats (n = 19) with infections of the urogenital tract, predominantly cystitis ( n = 15), followed by haematuria (n = 10) and dysuria (n = 6) (Table 1 and Table S1). The isolates were recultivated on 5% sheep blood agar, and DNA was extracted using the GenEluteTM Mammalian Genomic DNA Miniprep Kits by Sigma‐Aldrich (Sigma‐Aldrich by Merck kGaA, Darmstadt, Germany), according to the manufacturer's instructions. Antimicrobial susceptibility testing was performed by agar disc diffusion according to the CLSI standards (Clinical and Laboratory Standards Institute 2018). E. coli ATCC 25922 served as the quality control. Discs containing the following antimicrobial agents were used: ampicillin (10 µg); cefotaxime (30 µg); ceftazidime (30 µg); cefoxitin (30 µg); meropenem (10 µg); gentamicin (10 µg); tobramycin (10 µg); amikacin (30 µg); ciprofloxacin (5 µg); trimethoprim–sulfamethoxazole (1.25/23.75 µg); tetracycline (30 µg); chloramphenicol (30 µg); fosfomycin (200 µg); and nitrofurantoin (300 µg) (Becton Dickinson; Heidelberg, Germany). Due to the absence of these genes in the DNA microarray panel, isolates showing resistance to tetracycline or chloramphenicol were further tested for the presence of the tet(A) and tet(B) or cat resistance genes using PCR (Grünzweil et al. 2021 May 31). The quinolone resistance‐determining regions (QRDR) of gyrA and parC in ciprofloxacin‐resistant isolates were amplified by PCR and sequenced (Everett et al. 1996). Isolates were phylotyped using the quadruplex assignment method as previously described (Clermont et al. 2013 Feb). Clonal groups of E. coli isolates were determined by two‐locus sequence typing by combining data from fumC and fimH sequences (“CH‐clonotyping”) (Weissman et al. 2012), using CHTyper (Roer et al. 2018) hosted at the Center for Genomic Epidemiology (https://cge.cbs.dtu.dk/services/chtyper/, accessed on 1.10.2025). In addition to clonotyping, in an isolate displaying unique characteristics (i.e., ESBL phenotype) and belonging to CH40‐30, seven‐locus multi‐locus sequence typing (MLST) (Wirth et al. 2006) and an allele‐specific PCR were performed to identify the O25b clone of E. coli (Clermont et al. 2009). A set of virulence‐associated genes (Table S2) was determined using a custom‐made DNA microarray‐based technology from INTER‐ARRAY (INTER‐ARRAY by fzmb GmbH, Bad Langensalza, Germany) according to the manufacturer's instructions (Monecke et al. 2007, Bernreiter‐Hofer et al. 2021). Isolates resistant to ampicillin or displaying an ESBL phenotype were further analysed by the INTER‐ARRAY Genotyping Kit CarbaResist (INTER‐ARRAY by fzmb GmbH; Bad Langensalza, Germany; all information upon request under https://www.inter‐array.com/products/). All resistance‐associated genes integrated into the INTER‐ARRAY Genotyping Kit CarbaResist array were as previously described (formerly CarbDetect AS‐2) (Braun et al. 2018). TABLE 1Summarised molecular characterisation, antimicrobial resistance, and virulence profile of the E. coli isolates investigated. Resistance profileIsolatesHostDiagnosisPhylo‐groupCH‐clonotypingVirulence genesPhenotypeGenotype1430, 1431CatDysuriaB224‐102 cnf1, pic, fimH, papC, hlyA, iucD NR1355CatCystitisB214‐1463 cnf1, fimH, hlyA AMP, STX bla TEM, bla OXA‐2, sul2, dfrA5 1619CatChronic kidney diseaseB214‐2 cnf1, fimH, hlyA NR1319, 1594DogHaematuria (1319), cystitis (1594)B243‐1561 cnf1, fimH, hlyA NR2164CatHaematuriaB252‐286 cnf1, fimH, papC, hlyA, iucD NR2428DogCystitisB224‐1431 cnf1, pic, fimH, hlyA NR2455, 4160, 3157DogPyelonephritis (2455), cystitis (4160), haematuria (3157)B2103‐9 cnf1, fimH, hlyA NR2712DogNot knownB2103‐1629 cnf1, fimH, hlyA AMP bla TEM 2790CatNot knownB213‐223 cnf1, fimH, hlyA NR2771CatFLUTDB213‐5 astA, cnf1, fimH, hlyA NR2721, 3616DogNot known (2721), cystitis (3616)B2103‐9 astA, cnf1, fimH, hlyA NR1177, 3617DogCystitis (1177), not known (3617)B213‐9 astA, cnf1, fimH, hlyA NR970CatCystitisB213‐9 cnf1, fimH, hlyA NR959DogHaematuriaB224‐306 cnf1, pic, fimH, papC, hlyA, iucD NR747CatDysuriaB214‐10 cnf1, pic, fimH, papC, hlyA, iucD NR350DogCystitisB224‐2 cnf1, fimH, hlyA NR189CatPyelonephritisB214‐9 cnf1, pic, fimH, hlyA NR325DogNot knownB213‐2 cnf1, fimH, hlyA NR607DogNot knownB213‐223 cnf1, fimH, hlyA NR726CatChronic kidney diseaseB243‐new cnf1, fimH, hlyA NR3710DogCystitisB224‐new cnf1, fimH, hlyA NR3841, 3843CatAcute kidney disease (3841), cystitis (3843)B224‐13 cnf1, pic, fimH, papC, hlyA, iucD NR3850CatFLUTDB2103‐102 cnf1, pic, fimH, hlyA NR14,057DogCystitisB238‐9 cnf1, fimH, hlyA NR8CatHaematuriaB2103‐21 cnf1, fimH, hlyA NR3699DogHaematuriaB224‐9 cnf1, fimH, hlyA NR3068DogNot knownB224‐10 cnf1, pic, fimH, papC, hlyA, iucD NR4143CatCystitisB224‐new cnf1, fimH, hlyA NR4154DogProstatitisB2103‐9 cnf1, pic, fimH, hlyA NR473CatCystitisB224‐21 cnf1, fimH, hlyA NR2181DogHaematuriaB213‐102 astA, cnf1, pic, fimH, hlyA NR2484DogIrregular bladder wallB213‐27 cnf1, fimH, hlyA NR2623DogDysuriaB24‐13 astA, cnf1, pic, fimH, papC, hlyA, iucD NR2714DogHaematuriaB1103‐32 cnf1, fimH, papC, hlyA, iucD AMP, TET, STX bla TEM, bla ACT , tet(A), dfrA5 3248DogIncontinenceB2103‐9 cnf1, fimH, hlyA AMP, TET, STX bla TEM, aadA1 , tet(A), sul1, sul2, dfrA1, dfrA5 3679DogNot knownB224‐204 cnf1, f17‐G, fimH, K88ab, hlyA AMP, CHL, STX bla TEM, sul2, cat 703DogCystitisB2103‐new astA, cnf1, pic, fimH, hlyA NR1009DogDysuriaB213‐211 astA, cnf1, fimH, hlyA NR494DogHaematuriaB2319‐306 cnf1, fimH, hlyA NR1306DogBacteriuriaB224‐197 cnf1, fimH, hlyA NR3000CatDysuriaB214‐197 cnf1, fimH, hlyA NR4207CatFLUTDB214‐103 astA, cnf1, pic, fimH, hlyA NR3383DogHaematuriaB240‐30 fimH, papC, hlyA, iucD AMP, CTX, CAZ, CIP, TET, GEN, FOF bla CTX‐M15, bla ACT, bla OXA‐2, tet(A), dfrA5, aac(3')‐IVa, aadA1 Abbreviations: AMP, ampicillin; CTX, cefotaxime; CAZ, ceftazidime; CIP, ciprofloxacin; FLUTD, feline lower urinary tract disease; FOF, fosfomycin; GEN, gentamicin; NR, non‐resistant; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline.John Wiley & Sons, Ltd. Summarised molecular characterisation, antimicrobial resistance, and virulence profile of the E. coli isolates investigated. Abbreviations: AMP, ampicillin; CTX, cefotaxime; CAZ, ceftazidime; CIP, ciprofloxacin; FLUTD, feline lower urinary tract disease; FOF, fosfomycin; GEN, gentamicin; NR, non‐resistant; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline. Results 45 out of 51 isolates were susceptible to all antibiotics tested. Among other isolates, resistance to ampicillin (n = 1), ampicillin, trimethoprim–sulfamethoxazole and tetracycline (n = 2), or ampicillin, trimethoprim–sulfamethoxazole and chloramphenicol (n = 1) was observed. One isolate displayed an ESBL phenotype and was resistant to ẞ‐lactams (exclusive of cefoxitin and carbapenems), ciprofloxacin (amino acid substitutions were detected in the QRDR of gyrA (83Ser→Leu and 87Asp→Asn) and parC (80Ser→Ile 84Glu→Val)), tetracycline, gentamicin, and fosfomycin. Four isolates were multidrug‐resistant (Sweeney et al. 2018) (Table 1). The detected resistance genes (bla TEM, bla CTX, bla OXA‐2, sul1, sul2, dfrA1, dfrA5, tet(A), aac(3')‐IVa, catA) reflected the phenotypic findings well (Table 1). 50 out of 51 E. coli belonged to the phylogenetic group B2, and one isolate was assigned to phylogenetic group B1. Thirty‐four CH clonotypes were differentiated. CH103‐9 was the predominant clonotype (n = 7), along with more frequently occurring two isolates (CH24‐102 (n = 2); CH43‐1561(n = 2); CH13‐223 (n = 2); CH13‐5 (n = 2); CH13‐9 (n = 2); CH24‐13 (n = 2); CH38‐9 (n = 2)) showed clonal relatedness. An isolate belonging to B2‐CH40‐30 was positive for the O25b‐specific allele and confirmed as ST131 using seven loci MLST. All isolates showed the virulence factors fimH (51/51) and hlyA (51/51), determined via microarray. The virulence factors cnf1 (50/51), pic (15/51), papC (11/51), and iucD (11/51) were also frequently detected, with co‐occurrence of papC and iucD. Discussion The present study aimed to characterise haemolytic E. coli isolated from samples of dogs and cats with urinary infections, using pheno‐ and genotyping methods. E. coli associated with UTI cases in Austrian cats and dogs are, until now, widely characterised (Loncaric et al. 2020; Marques et al. 2016). In the present study, all but one isolate belonged to the phylogroup B2. E. coli isolates from the urinary tracts of humans and animals, particularly those causing ExPEC infections, are often linked to this phylogroup (Aurich et al. 2023; Siqueira et al. 2021; Jousserand et al. 2025; Valat et al. 2020; Osugui et al. 2014; Oh and Park, 2025; Johnson et al. 2009). In addition to hlyA, the adhesion gene fimH, which is referred to as a major virulence‐associated gene (VAG) of UPEC (Terlizzi et al. 2017), was observed in all isolates. Consistent with previous studies describing VAG's associated with UPEC from companion animals, the toxin‐encoding gene cnf1 was observed in all but one isolate, while the pic gene (encoding a serine protease), the iucD gene (which is only found in virulent E. coli strains), and papC (encoding P‐fimbriae) were frequently detected (Aurich et al. 2023; Ksiezarek et al. 2021; Jousserand et al. 2025; Valat et al. 2020; Osugui et al. 2014; Johnson et al. 2009; Zogg et al. 2018). Although the predominance of phylogroup B2 was expected, the complete conservation of the cnf1 and hlyA linkage within this geographical cohort offers novel insights into the regional clonal stability of UPEC. Other VAG's, were infrequently observed, such as astA, which encodes the enteroaggregative heat‐stable toxin EAST1, usually but not exclusively associated with Enteroaggregative E. coli (EAEC), or the K88 fimbriae (also known as F4 fimbriae) and f17‐G fimbriae. This is in concordance with other studies (Jousserand et al. 2025; Johnson et al. 2009). One isolate from the B1 phylogroup revealed associations with UPEC‐specific VAGs. While phylogroup B1 E. coli are typically considered commensal strains in the intestines of healthy humans and animals (Oh and Park 2025), they have been occasionally isolated from UTIs in companion animals (Aurich et al. 2023; Jousserand et al. 2025; Valat et al. 2020; Osugui et al. 2014; Oh and Park 2025; Johnson et al. 2009; Zogg et al. 2018). Antibiotic phenotypic and genotypic resistance was a rare observation in the present study. While the majority of isolates (88.2%) were susceptible to all tested antibiotics, four out of six isolates displayed a multidrug‐resistant profile (Sweeney et al. 2018). This low antibiotic resistance rate in canine and feline UPEC isolates, mainly belonging to the phylogroup B2, is consistent with the resistance situation observed in previous studies (Aurich et al. 2023; Jousserand et al. 2025; Valat et al. 2020; Zogg et al. 2018). The detection of a single isolate (3383, displaying an ESBL phenotype) belonging to B2 (phylotype) ‐O25b, (serotype) ‐ST131, (sequence type), and ‐CH40‐30 (clonotype), carrying bla CTX‐M‐15 and bla OXA‐2, and exhibiting ciprofloxacin resistance, represents an isolated observation that warrants attention. Recognised as a major human‐associated “high‐risk” pandemic pathogen, the B2‐O25b‐ST131 clone has been universally classified as an ExPEC and/or UPEC and is responsible for various infections in humans and animals, including those with UTIs (Jousserand et al. 2025; Clark and Maresso 2021; Rogers et al. 2011; Nicolas‐Chanoine et al. 2014; Bonnet et al. 2021; Pitout and Finn 2020). Until present, among animals in Austria, the B2‐O25b‐ST131 clone has been sporadically detected from Austrian animals, including wildlife (Loncaric et al. 2013), canine prostate (Loncaric et al. 2020), porcine intestine–associated samples (Bernreiter‐Hofer et al. 2021), and very recently from a faecal sample (Saria et al. 2025). Besides B2‐O25b‐ST131‐CH40‐30, belonging to E. coli clonal complex (CC) 131, other clonotypes detected in the present study have also been observed in UPECs from recent studies. These are CH13‐27 and CH13‐223 belonging to E. coli CC12, CH24‐9, CH24‐10, CH24‐13, CH24‐102, and CH24‐1431 to CC73; CH14‐2 to CC127; CH13‐5 to CC141; and, finally, CH103‐9 to CC372 (Jousserand et al. 2025; Valat et al. 2020; Oh and Park 2025; Zogg et al. 2018). While E. coli isolates belonging to CC131, CC73, CC12, and CC141 have been reported as commonly isolated from humans (Manges et al. 2019; Emery et al. 2023; Riley 2014), isolates belonging to CC372 have been primarily associated with dogs (Aurich et al. 2023; Jousserand et al. 2025; Valat et al. 2020). This study has several limitations. First, our analysis has inherent selection bias due to restriction to haemolytic E. coli; consequently, the virulence and resistance potential of non‐haemolytic strains causing UTIs require further investigation. Second, the panel of selected VAGs was limited. These data could be enriched in a future study by including a larger collection of strains and utilising whole‐genome sequencing for a more comprehensive characterisation. Finally, the low presence of resistant isolates restricts broader epidemiological insights into antimicrobial resistance within canine and feline UTIs. Conclusions Although the majority of isolates were susceptible to all tested antibiotics, the virulence potential of these strains poses a relevant concern for both public and animal health. Consequently, the risk of human infection or colonisation from these isolates remains to be fully determined. In a clinical context, our data indicate that a significant proportion of E. coli UTIs in companion animals can still be successfully managed with existing antibiotic therapies. Nevertheless, the existence of multi‐drug‐resistant pet E. coli strains with a zoonotic potential underscores the critical need for a continuous “One Health” approach to monitor and control their virulence and antimicrobial resistance. Author Contributions Sarah Büttner: Formal Analysis, Investigation, Visualization, Writing – Original Draft Preparation. Joachim Spergser: Funding Acquisition, Resources, Methodology, Writing – Review & Editing. Olga Makarova: Data Curation, Methodology, Validation, Writing – Original Draft Preparation, Writing – Review & Editing. Michael P. Szostak: Data Curation, Investigation, Validation, Writing – Review & Editing. Adriana Cabal Rosel: Investigation, Methodology, Writing – Review & Editing. Werner Ruppitsch: Investigation, Methodology, Writing – Review & Editing. Sabine Schäfer‐Somi: Resources, Validation, Writing – Review & Editing. Elke Müller: Formal Analysis, Investigation, Sascha D. Braun: Investigation, Methodology, Writing – Review & Editing. Stefan Monecke: Conceptualization, Methodology, Writing – Review & Editing. Ralf Ehricht: Conceptualization, Resources, Methodology, Writing – Review & Editing. Frank Künzel: Conceptualization, Investigation, Resources, Validation, Writing – Review & Editing. Igor Loncaric: Conceptualization, Formal Analysis, Investigation, Methodology, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing. Funding The authors have nothing to report. Ethics Statement All samples were received from third parties and, therefore, are not subject to the reporting obligations of the Ethics and Animal Welfare Commission of the University of Veterinary Medicine in Vienna. Supporting information Table S1: All clinical data Table S2: Virulence‐associated genes tested